Journal of the Neurological Sciences
Volume 292, Issue 1 , Pages 52-56 , 15 May 2010

Poor recovery after the first two attacks of multiple sclerosis is associated with poor outcome five years later

  • Thomas F. Scott

      Affiliations

    • Corresponding Author InformationCorresponding author. 420 East North Ave., Suite 206, Pittsburgh, PA 15212, United States. Tel.: +1 412 359 8850; fax: +1 412 359 8878.
    • ,
  • Carol J. Schramke

Received 18 November 2009 ,Revised 2 February 2010 ,Accepted 8 February 2010.

References 

  1. Pittock SJ, Weinshenker BG, Noseworthy JH, et al. Not every patient with multiple sclerosis should be treated at time of diagnosis. Arch Neurol. 2006;63:611–6114
  2. Ransohoff RM. Natalizumab for multiple sclerosis. N Eng J Med. 2007;356:2622–2629
  3. Scott TF, Schramke CJ, Novero J, Chieffe C. Short-term prognosis in early relapsing–remitting multiple sclerosis. Neurology. 2000;55:689–693
  4. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol. 2001;50:121–127
  5. Kurtzke J. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444–1452
  6. Pittock SJ, Mayr WT, McClelland RL, et al. Disability profile of MS did not change over 10years in a population-based prevalence cohort. Neurology. 2004;62:601–606
  7. Tremlett H, Paty D, Devonshire V. Disability progression in multiple sclerosis is slower than previously reported. Neurology. 2006;66:172–177
  8. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain. 2003;126:770–782
  9. Mowry EM, Pesic M, Grimes B, Deen S, Bacchetti P, Waubant E. Demyelinating events in early multiple sclerosis have inherent severity and recovery. Neurology. 2009;72:602–608
  10. Kurtzke JF, Beebe GW, Nagler B, Kurland LT, Auth TL. Studies on the natural history of multiple sclerosis—8. Early prognostic features of the later course of the illness. J Chronic dis. 1977;819–830
  11. Pittock SJ, McClelland RL, Mayr WT, et al. Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study. Ann Neurol. 2004;56:303–306
  12. Weinshenker BG, Rice GPA, Noseworthy JH, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome. Brain. 1991;114:1045–1056
  13. Confavreux C, Aimard G, Devic M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain. 1980;103:281–300
  14. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain. 1993;116(part 1):117–134
  15. Visscher BR, Liu KS, Clark VA, Detels R, Malmgren RM, Dudley JP. Onset symptoms as predictors of mortality and disability in multiple sclerosis. Acta Neurol Scand. 1984;70:321–328
  16. Miller DH, Hornabrook RW, Purdie G. The natural history of multiple sclerosis: a regional study with some longitudinal data. J Neurol Neurosurg Psychiatry. 1992;55:341–346
  17. Langer-Gould A, Popat RA, Huang SM, et al. Clinical and demographic predictors of long-term disability in patients with relapsing–remitting multiple sclerosis a systematic review. Arch Neurol. 2006;63:1686–1691
  18. Verjans E, Theys P, Delmotte P, Carton H. Clinical parameters and intrathecal IgG synthesis as prognostic features in multiple sclerosis. J Neurol. 1983;229:115–165
  19. Riise T, Gronning M, Fernandez O, et al. Early prognostic factors for disability in multiple sclerosis, a European multi-center study. Acta Neurol Scand. 1992;85:212–218
  20. Gauthier SA, Mandel M, Guttmann CRG, et al. Predicting short-term disability in multiple sclerosis. Neurology. 2007;68:2059–2065
  21. Bergamaschi R, Berzuini C, Romani A, Cosi V. Predicting secondary progression in relapsing–remitting multiple sclerosis: a Bayesian analysis. J Neurol Sci. 2001;189:13–21
  22. Roxburgh RH, Seaman SR, Masterman T, et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology. 2005;64:1144–1151
  23. Rio J, Nos C, Tintore M, et al. Defining the response to interferon-β in relapsing–remitting multiple sclerosis patients. Ann Neurol. 2006;59:344–352

PII: S0022-510X(10)00065-1

doi: 10.1016/j.jns.2010.02.008

Journal of the Neurological Sciences
Volume 292, Issue 1 , Pages 52-56 , 15 May 2010

Article Tools

* Image Usage & Resolution